Moderna Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Moderna kazanç ve gelirin sırasıyla yıllık 44% ve 12.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 44.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -30.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

43.2%

Kazanç büyüme oranı

43.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	35.6%
Gelir büyüme oranı	11.1%
Gelecekteki özkaynak getirisi	-31.9%
Analist kapsamı	Good
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:0QF - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	4,219	-2,350	-1,799	-1,221	18
12/31/2025	3,264	-3,318	-2,718	-2,293	23
12/31/2024	3,217	-3,778	-3,118	-2,760	23
6/30/2024	5,050	-5,867	-3,979	-3,241	N/A
3/31/2024	5,153	-5,968	-3,672	-2,882	N/A
12/31/2023	6,848	-4,714	-3,825	-3,118	N/A
9/30/2023	9,121	-3,466	-2,657	-2,078	N/A
6/30/2023	10,654	1,207	-754	-226	N/A
3/31/2023	15,059	4,784	612	993	N/A
12/31/2022	19,263	8,362	4,581	4,981	N/A
9/30/2022	21,390	11,765	6,201	6,629	N/A
6/30/2022	22,995	14,055	9,215	9,653	N/A
3/31/2022	22,600	14,638	13,031	13,412	N/A
12/31/2021	18,471	12,202	13,336	13,620	N/A
9/30/2021	11,831	7,061	11,386	11,574	N/A
6/30/2021	7,019	3,495	9,083	9,191	N/A
3/31/2021	2,732	598	5,007	5,104	N/A
12/31/2020	803	-747	1,959	2,027	N/A
9/30/2020	246	-597	613	664	N/A
6/30/2020	106	-488	-374	-336	N/A
3/31/2020	52	-505	-451	-421	N/A
12/31/2019	60	-514	-491	-459	N/A
9/30/2019	82	-535	-489	-451	N/A
6/30/2019	106	-499	-482	-424	N/A
3/31/2019	122	-459	-445	-364	N/A
12/31/2018	135	-402	-437	-331	N/A
9/30/2018	192	-299	-447	-343	N/A
6/30/2018	192	-280	-412	-305	N/A
3/31/2018	199	-266	N/A	-350	N/A
12/31/2017	206	-270	N/A	-331	N/A
12/31/2016	108	-230	N/A	67	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0QF önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 0QF önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 0QF önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 0QF şirketinin gelirinin (yıllık 12.1% ) German pazarından (yıllık 5.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0QF şirketinin gelirinin (yıllık 12.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0QF 3 yıl içinde kârsız olması bekleniyor.

Moderna Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Recent updates

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

New major risk - Share price stability

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

New major risk - Revenue and earnings growth

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 17%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Investor sentiment improves as stock rises 16%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin